“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s79. doi:10.25251/skin.4.supp.79.